Rocapuldencel-T

Drug Profile

Rocapuldencel-T

Alternative Names: AGS-003; AGS-003-LNG

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Argos Therapeutics Inc
  • Developer Argos Therapeutics Inc; GU Research Network; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Non-small cell lung cancer

Most Recent Events

  • 18 Apr 2017 Efficacy data from a post-hoc analysis and immunogenicity data from a pre-defined immunological analysis of the phase III ADAPT trial in Renal cell carcinoma released by Argos Therapeutics
  • 14 Dec 2016 Argos Therapeutics Enters into strategic research agreement with Personalis for use of ACE ImmunoID™ next-generation sequencing (NGS) platform
  • 07 Dec 2016 Argos Therapeutics announces intention to submit BLA to the US FDA for rocapuldencel-T
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top